CA3053294A1 - Method for generating t cells progenitors - Google Patents

Method for generating t cells progenitors Download PDF

Info

Publication number
CA3053294A1
CA3053294A1 CA3053294A CA3053294A CA3053294A1 CA 3053294 A1 CA3053294 A1 CA 3053294A1 CA 3053294 A CA3053294 A CA 3053294A CA 3053294 A CA3053294 A CA 3053294A CA 3053294 A1 CA3053294 A1 CA 3053294A1
Authority
CA
Canada
Prior art keywords
cells
tnf
alpha
cell
medium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3053294A
Other languages
English (en)
French (fr)
Inventor
Isabelle Andre
Marina Cavazzana
Kuiying MA
John TCHEN
Tayebeh-Shabi Soheili
Ranjita Devi Moirangthem
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fondation Imagine - Institut Des Maladies Genetiques
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Fondation Imagine - Institut Des Maladies Genetiques
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Descartes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fondation Imagine - Institut Des Maladies Genetiques, Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite Paris Descartes filed Critical Fondation Imagine - Institut Des Maladies Genetiques
Publication of CA3053294A1 publication Critical patent/CA3053294A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/25—Tumour necrosing factors [TNF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
CA3053294A 2017-02-13 2018-02-12 Method for generating t cells progenitors Pending CA3053294A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17305161 2017-02-13
EP17305161.6 2017-02-13
PCT/EP2018/053406 WO2018146297A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Publications (1)

Publication Number Publication Date
CA3053294A1 true CA3053294A1 (en) 2018-08-16

Family

ID=58185453

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3053294A Pending CA3053294A1 (en) 2017-02-13 2018-02-12 Method for generating t cells progenitors

Country Status (17)

Country Link
US (5) US20200046767A1 (https=)
EP (2) EP4067482A1 (https=)
JP (2) JP7164798B2 (https=)
KR (1) KR102666158B1 (https=)
CN (1) CN110506110B (https=)
AU (1) AU2018217404B2 (https=)
BR (1) BR112019016672A8 (https=)
CA (1) CA3053294A1 (https=)
DK (1) DK3580330T3 (https=)
ES (1) ES2931530T3 (https=)
HU (1) HUE060548T2 (https=)
IL (1) IL268641B2 (https=)
MA (1) MA47541A (https=)
PL (1) PL3580330T3 (https=)
PT (1) PT3580330T (https=)
WO (1) WO2018146297A1 (https=)
ZA (1) ZA201905470B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T
CA3077344A1 (en) * 2017-09-29 2019-04-04 Regents Of The University Of Minnesota Methods of making, expanding, and using a human progenitor t cell
CA3091158A1 (en) 2018-02-14 2019-08-22 Sunnybrook Research Institute Method for generating cells of the t cell lineage
AU2019336221B2 (en) 2018-09-07 2025-05-15 Wisconsin Alumni Research Foundation Generation of hematopoietic progenitor cells from human pluripotent stem cells
EP3963082A4 (en) * 2019-05-01 2023-01-04 Immunebridge Inc. Methods of making oligopotent and unipotent precursors
EP3986427A1 (en) * 2019-06-24 2022-04-27 Childrens Hospital Los Angeles Bcl11b overexpression to enhance human thymopoiesis and t cell function
JP2023502965A (ja) * 2019-11-14 2023-01-26 ウィリアム ザンドストラ，ピーター 前駆ｔ細胞を製造するための培地処方および方法
JPWO2021200901A1 (https=) * 2020-03-31 2021-10-07
JP2023553313A (ja) 2020-11-30 2023-12-21 チョ ファーマ インコーポレイテッド 細胞を富化するための抗体
AU2022228364A1 (en) * 2021-03-05 2023-09-14 Factor Bioscience Inc. Engineered immune cell therapies
WO2022248354A1 (en) * 2021-05-25 2022-12-01 Universiteit Gent Generating t cell precursors via agonizing tumor necrosis factor receptor 2
WO2023079082A1 (en) * 2021-11-04 2023-05-11 Aphp (Assistance Publique - Hôpitaux De Paris) Method for generating nk cells
FR3130843A1 (fr) * 2021-12-21 2023-06-23 Universite Claude Bernard Lyon 1 Cellule progéniteur des lymphocytes T exprimant de manière régulée un transgène d’intérêt
JP2026504155A (ja) 2023-01-27 2026-02-03 ノッチ セラピューティクス（カナダ）インコーポレイテッド 幹細胞／前駆細胞からｔ細胞系統集団を生成するための方法
KR20250152088A (ko) * 2023-02-22 2025-10-22 메이라지티엑스 셀 테라피스 흉선 재생 방법
US20250332260A1 (en) 2024-04-10 2025-10-30 Garuda Therapeutics, Inc. Immune compatible cells for allogeneic cell therapies to cover global, ethnic, or disease-specific populations
WO2025219552A1 (en) 2024-04-17 2025-10-23 Assitance Publique Hopitaux De Paris Method for producing t cell progenitors from human pluripotent stem cells
CN119709836B (zh) * 2024-12-21 2025-08-08 湖南农业大学 OsProT2基因在调控水稻镉含量、镉耐受性及产量中的应用和方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093531A (en) 1997-09-29 2000-07-25 Neurospheres Holdings Ltd. Generation of hematopoietic cells from multipotent neural stem cells
WO1999028486A1 (en) 1997-12-04 1999-06-10 Duke University Methods of isolating and using cd7+cd34-lin-hematopoietic cells
WO2009097140A1 (en) 2008-01-30 2009-08-06 Memorial Sloan-Kettering Cancer Center Methods for off -the -shelf tumor immunotherapy using allogeneic t-cell precursors
EP2331679B1 (en) 2008-09-12 2017-04-19 Cryopraxis Criobiologia LTDA. Ischemic tissue cell therapy
AU2009311232B2 (en) * 2008-11-07 2014-10-30 Sunnybrook Health Sciences Centre Human progenitor T-cells
US8871510B2 (en) 2009-12-03 2014-10-28 University Of Utah Research Foundation Methods for generating T lymphocytes from hematopoietic stem cells
CA2795627C (en) 2010-04-09 2023-03-14 Fred Hutchinson Cancer Research Center Compositions and methods for providing hematopoietic function without hla matching
US10391126B2 (en) 2011-11-18 2019-08-27 Board Of Regents, The University Of Texas System CAR+ T cells genetically modified to eliminate expression of T-cell receptor and/or HLA
EP2788476B1 (en) * 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2014110353A1 (en) 2013-01-11 2014-07-17 The Trustees Of The University Of Pennsylvania Notch ligand bound bicompatible substrates and their use in bone formation
EP3027755B1 (en) * 2013-08-02 2019-10-09 The Regents of The University of California Engineering antiviral t cell immunity through stem cells and chimeric antigen receptors
US20170128556A1 (en) 2013-12-26 2017-05-11 Thyas Co. Ltd. Immunotherapy using t precursor cells derived from pluripotent stem cells having rearranged t cell receptor genes
CA2945388A1 (en) 2014-04-23 2015-10-29 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) for use in therapy and methods for making the same
CN106062185A (zh) * 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
WO2016039933A1 (en) 2014-09-11 2016-03-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lentiviral vector for treating hemoglobin disorders
FR3026744B1 (fr) * 2014-10-06 2024-04-19 Hopitaux Paris Assist Publique Methode de generation de progeniteurs de cellules t
JP2018518181A (ja) * 2015-06-17 2018-07-12 ザ ユーエービー リサーチ ファンデーション 血液細胞系列の細胞に機能的ポリペプチドを導入するためのＣＲＩＳＰＲ／Ｃａｓ９複合体
WO2017173551A1 (en) 2016-04-08 2017-10-12 The Governing Council Of The University Of Toronto Method for generating progenitor t cells from stem and/or progenitor cells and use of same
ES2931530T3 (es) * 2017-02-13 2022-12-30 Hopitaux Paris Assist Publique Método para generar progenitores de células T

Also Published As

Publication number Publication date
US20210169934A1 (en) 2021-06-10
US20200390817A1 (en) 2020-12-17
IL268641B1 (en) 2024-06-01
IL268641B2 (en) 2024-10-01
PT3580330T (pt) 2022-12-06
KR20190117550A (ko) 2019-10-16
JP7164798B2 (ja) 2022-11-02
KR102666158B1 (ko) 2024-05-16
RU2019125600A3 (https=) 2021-11-03
US20210169935A1 (en) 2021-06-10
EP4067482A1 (en) 2022-10-05
EP3580330A1 (en) 2019-12-18
WO2018146297A1 (en) 2018-08-16
RU2019125600A (ru) 2021-03-15
ZA201905470B (en) 2024-12-18
US11426430B2 (en) 2022-08-30
AU2018217404A2 (en) 2019-09-19
BR112019016672A2 (pt) 2020-04-14
DK3580330T3 (da) 2022-12-05
ES2931530T3 (es) 2022-12-30
MA47541A (fr) 2019-12-18
JP2020513844A (ja) 2020-05-21
HUE060548T2 (hu) 2023-03-28
BR112019016672A8 (pt) 2022-11-22
JP2022185024A (ja) 2022-12-13
PL3580330T3 (pl) 2023-01-16
CN110506110A (zh) 2019-11-26
US11638723B2 (en) 2023-05-02
US20230293586A1 (en) 2023-09-21
CN110506110B (zh) 2024-09-06
EP3580330B1 (en) 2022-08-31
AU2018217404A1 (en) 2019-09-05
IL268641A (en) 2019-10-31
AU2018217404B2 (en) 2024-03-28
US20200046767A1 (en) 2020-02-13
US11642376B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
US20230293586A1 (en) Method for generating t cells progenitors
Shankar et al. Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies
Matosevic Viral and nonviral engineering of natural killer cells as emerging adoptive cancer immunotherapies
US12071635B2 (en) Method for generating T-cell progenitors
AU2015288052A1 (en) Manufacture and cryopreservation of fucosylated cells for therapeutic use
Kremer et al. Membrane-bound IL-2 improves the expansion, survival, and phenotype of CAR Tregs and confers resistance to calcineurin inhibitors
Netsrithong et al. Advances in adoptive cell therapy using induced pluripotent stem cell-derived T cells
ES2409128T3 (es) Procedimientos de mejora de anidamiento e injerto de células madre
TW202216174A (zh) 使ｎｋ細胞與抗體之結合穩定化之方法及其利用
HK40081656A (en) Method for generating t cells progenitors
RU2797260C2 (ru) Способ получения предшественников т-клеток
HK40017982A (en) Method for generating t cells progenitors
HK40017982B (en) Method for generating t cells progenitors
WO2025220666A1 (en) Cytotoxic Lymphocytes Expressing Variable Region-Deleted T Cell Receptors
Shukla Controlled generation of progenitor T-Cells from hematopoietic stem cells and pluripotent stem cells
IL324860A (en) CarthyTreg cells, their compositions and uses in immunotherapy
Guerrettaz Aging-associated changes in B-lymphopoiesis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230210

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20240730

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241223

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250625

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250625

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250710

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20251110

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251127

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260113

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113